Neurovance Completes Enrollment in Human Abuse Liability Study for Centanafadine (Formerly Called EB-1020) for Adult …

Neurovance, Inc. today announced that it has completed enrollment in a human abuse liability study of centanafadine . Centanafadine is a novel non-stimulant being developed for the treatment of adults with attention deficit hyperactivity disorder .

from Content Keyword RSS http://ift.tt/1oGPfj8 http://ift.tt/eA8V8J

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s